Icon (NASDAQ:ICLR) Director Sells 841 Shares

Icon Plc (NASDAQ:ICLR) Director Ronan Martin Murphy sold 841 shares of Icon stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $164.29, for a total transaction of $138,167.89. Following the completion of the sale, the director owned 3,847 shares of the company’s stock, valued at $632,023.63. This trade represents a 17.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Icon Stock Performance

NASDAQ:ICLR traded up $1.59 during trading hours on Wednesday, hitting $167.17. 804,300 shares of the company were exchanged, compared to its average volume of 1,385,101. The company has a debt-to-equity ratio of 0.23, a current ratio of 0.95 and a quick ratio of 0.95. Icon Plc has a 52-week low of $66.57 and a 52-week high of $203.91. The stock has a market capitalization of $12.80 billion, a price-to-earnings ratio of 39.24, a PEG ratio of 6.88 and a beta of 1.21. The company’s 50 day moving average price is $161.47 and its 200-day moving average price is $134.31.

Icon (NASDAQ:ICLR) last posted its quarterly earnings results on Thursday, July 30th. The medical research company reported $2.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.55 by $0.01. The business had revenue of $2.06 billion during the quarter, compared to analysts’ expectations of $2 billion. Icon had a net margin of 3.99% and a return on equity of 8.02%. The business’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter last year, the company posted $3.26 earnings per share. As a group, research analysts forecast that Icon Plc will post 9.57 earnings per share for the current year.

Icon News Summary

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Icon’s latest quarterly results modestly exceeded expectations: adjusted EPS was $2.56 versus the $2.55 consensus, while revenue reached $2.06 billion, above the $2.00 billion estimate and up 2.3% year over year. Analysts expect approximately $9.57 in full-year EPS, providing a fundamental support for the stock.
• Positive Sentiment: Recent analyst actions have generally been constructive. BMO Capital Markets raised its price target to $187 and Mizuho increased its target to $190, both maintaining outperform ratings. The consensus target is $170.40, modestly above the latest trading level, although the overall consensus rating remains “Hold.”
• Positive Sentiment: Short interest is reported at zero shares, indicating no measurable bearish short-selling pressure or potential forced-selling overhang.
• Neutral Sentiment: CEO Barry Balfe sold 382 shares worth about $62,675, while CFO Nigel Clerkin sold 2,267 shares worth approximately $372,445. Directors John Climax and Linda Grais each sold 841 shares at about $164.29. The filings state that all transactions were made to cover tax-withholding obligations tied to vested equity awards, reducing their usefulness as a signal of declining confidence. SEC insider transaction filing
• Negative Sentiment: Despite the revenue beat, quarterly EPS fell from $3.26 a year earlier, and Icon’s reported net margin was only 3.99%. The stock also carries a high valuation, with a price-to-earnings ratio near 39 and a PEG ratio of 6.88, leaving it sensitive to any slowdown in clinical-research demand or earnings growth.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Royal Bank Of Canada upgraded Icon from a “sector perform” rating to an “outperform” rating and boosted their price target for the company from $126.00 to $185.00 in a research note on Thursday, June 25th. JPMorgan Chase & Co. raised their price objective on Icon from $130.00 to $155.00 and gave the stock a “neutral” rating in a research note on Thursday, June 25th. William Blair raised Icon to a “strong-buy” rating in a report on Thursday, July 30th. Mizuho upped their target price on Icon from $180.00 to $190.00 and gave the company an “outperform” rating in a research report on Friday, June 26th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $165.00 price target on shares of Icon in a report on Friday, May 29th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $170.40.

Institutional Investors Weigh In On Icon

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP raised its stake in shares of Icon by 26.6% during the 3rd quarter. Wellington Management Group LLP now owns 4,637,137 shares of the medical research company’s stock valued at $811,499,000 after buying an additional 975,268 shares during the last quarter. Orbis Allan Gray Ltd boosted its stake in shares of Icon by 1.8% in the fourth quarter. Orbis Allan Gray Ltd now owns 4,214,661 shares of the medical research company’s stock worth $767,996,000 after buying an additional 75,843 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Icon by 9.6% in the fourth quarter. Invesco Ltd. now owns 3,756,896 shares of the medical research company’s stock worth $684,582,000 after buying an additional 329,266 shares during the last quarter. Principal Financial Group Inc. grew its holdings in Icon by 10.3% during the first quarter. Principal Financial Group Inc. now owns 3,311,771 shares of the medical research company’s stock worth $366,481,000 after acquiring an additional 310,236 shares during the period. Finally, Franklin Resources Inc. raised its position in Icon by 8.7% during the fourth quarter. Franklin Resources Inc. now owns 2,993,336 shares of the medical research company’s stock valued at $545,410,000 after acquiring an additional 239,808 shares in the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.